What Is Pre-Excitation Syndrome and How Is It Treated?

Pre-excitation syndrome is a condition in which an extra electrical connection between the upper and lower chambers of the heart allows impulses to bypass the normal conduction system, sometimes triggering dangerously fast heart rhythms. The most familiar form, Wolff-Parkinson-White (WPW) syndrome, was first fully described in 1930 and has since become one of the most thoroughly studied rhythm disorders in cardiology.¹ For many people the extra pathway causes no trouble at all, but for others it can set off racing heartbeats or, in rare cases, a life-threatening emergency. Treatment ranges from watchful waiting to medication to a catheter procedure that eliminates the pathway with a success rate above 90 percent.

The Extra Pathway and What It Does

In a normal heart, electrical signals travel from the upper chambers (atria) down to the lower chambers (ventricles) through a single gateway called the atrioventricular (AV) node. That gateway deliberately slows the signal, giving the ventricles time to fill before they contract. In pre-excitation, an additional strand of muscle tissue bridges the atria and ventricles somewhere around the valve rings. Because this accessory pathway does not slow the signal the way the AV node does, part of the ventricle gets activated earlier than it should. That premature activation is visible on a standard electrocardiogram as a slurred upstroke at the beginning of each heartbeat, called a delta wave.²

The delta wave is the hallmark of WPW, but not every accessory pathway produces one. Some pathways only conduct signals backward, from ventricle to atrium, which means they never show the classic ECG pattern during a normal heartbeat. These “concealed” pathways can still participate in abnormal heart rhythms. Still other variant pathways have unusual properties, such as slow conduction that mimics a second AV node, making them tricky to identify even during specialized electrical studies of the heart.³

How Pre-Excitation Causes Fast Heart Rhythms

An accessory pathway creates the possibility of a short circuit. An electrical impulse can travel down the normal AV node to the ventricles, then loop back up through the accessory pathway to the atria, and repeat the cycle over and over. This reentrant loop produces a rapid, regular heartbeat called atrioventricular reentrant tachycardia, or AVRT. The most common form, orthodromic AVRT, sends the signal forward through the AV node and backward through the accessory pathway. Because the ventricles are activated through the normal route, the ECG during the episode usually shows a fast but narrow heartbeat that looks similar to other types of rapid rhythm originating above the ventricles.⁴

Less commonly, the circuit runs the other direction: forward through the accessory pathway and backward through the AV node. This antidromic AVRT produces a wide, bizarre-looking heartbeat on the monitor that can be difficult to tell apart from ventricular tachycardia, a more dangerous rhythm that originates in the ventricles themselves. The distinction matters because the wrong treatment for one can worsen the other. In some situations, the accessory pathway is not even part of the circuit but acts as a bystander, conducting signals to the ventricles during a rhythm that is being maintained by a different mechanism entirely. These bystander episodes also produce wide, fast heartbeats that look alarming on a monitor.⁴

When Pre-Excitation Becomes Dangerous

Most episodes of AVRT are uncomfortable but not deadly. The real danger arises when a person with an accessory pathway develops atrial fibrillation, an erratic, rapid quivering of the upper chambers. Normally the AV node acts as a bottleneck, preventing most of those chaotic signals from reaching the ventricles. But if the accessory pathway can conduct quickly in the forward direction, it lets far more impulses through, driving the ventricles at extremely high rates. This “pre-excited atrial fibrillation” can push heart rates well above 200 or even 300 beats per minute. At those speeds the ventricles cannot pump effectively, and the rhythm can deteriorate into ventricular fibrillation, which is cardiac arrest.⁵⁶

This is why emergency treatment of a fast, wide rhythm in someone with known WPW follows different rules than the treatment of other fast rhythms. Drugs that slow conduction through the AV node, such as certain calcium-channel blockers or digoxin, can actually make the situation worse by pushing more traffic through the accessory pathway. Emergency providers are taught to avoid those drugs and use electrical cardioversion or specific antiarrhythmic agents instead.

Figuring Out Who Is at Risk

Plenty of people walk around with a delta wave on their ECG and never experience symptoms. The challenge for clinicians is identifying which of those individuals harbor a pathway capable of conducting fast enough to pose a threat. Several risk markers have been identified: younger age, male sex, a posteroseptal pathway location, associated structural heart disease, the ability of the pathway to conduct signals at very short intervals of 250 milliseconds or less, and the ability to trigger sustained tachycardia or atrial fibrillation during electrical testing.⁷ In children and adolescents, the same cutoff of 250 milliseconds is used during invasive electrophysiology studies to define “adverse” pathway properties.⁸

One non-invasive clue comes from exercise testing. In roughly one in five people with WPW, the delta wave vanishes abruptly during exercise as the heart rate climbs. When the pre-excitation disappears like a light switch being flipped, it suggests the accessory pathway’s conducting ability is relatively limited, placing that person in a lower-risk category for sudden dangerous rhythms.⁹ If the delta wave persists even at high heart rates, further evaluation with invasive testing is warranted.

Medication as Treatment

Drugs do not cure pre-excitation, but they can suppress or slow conduction through the accessory pathway enough to prevent episodes of tachycardia. Flecainide, a sodium-channel blocker, is one of the better-studied options. When given intravenously, it terminates ongoing AVRT episodes in more than 80 percent of cases. As a daily oral medication it prevents recurrences in over 60 percent of patients, though it occasionally causes a paradoxical incessant tachycardia that is difficult to stop. Combining flecainide with a beta-blocker improves long-term results.¹⁰

Other antiarrhythmic drugs, including propafenone and amiodarone, are also used depending on the clinical scenario. For people who have infrequent, well-tolerated episodes and prefer not to take daily medication, a “pill-in-the-pocket” strategy sometimes works: they carry a single dose of an antiarrhythmic drug and take it only when an episode starts. But medication has real limits. It does not eliminate the accessory pathway, side effects can be significant, and it does not provide the definitive protection against sudden death that ablation offers. For these reasons, drugs are increasingly used as a bridge or a stopgap rather than a long-term plan.

Catheter Ablation and Its Success Rates

The definitive treatment for pre-excitation is catheter ablation: threading a thin, flexible tube through a blood vessel into the heart and delivering focused energy to destroy the accessory pathway. A meta-analysis pooling data from multiple studies found a success rate of about 94 percent, with a recurrence rate around 6 percent and a complication rate of roughly 1 percent.¹¹ Another large single-center series reported acute success in 97 percent of 558 procedures, with about 8 percent of patients experiencing a recurrence during follow-up.¹²

When ablation fails the first time, a repeat procedure succeeds in about 91 percent of cases according to a multicentre study tracking outcomes over seven years. Failures tend to cluster around specific pathway locations and specific procedural limitations from the first attempt, such as inaccurate mapping of the pathway’s location or inability to reach it with the catheter.¹³ Multiple pathways, pathways buried deep in the coronary sinus, and pathways sitting on the heart’s outer surface (epicardial) require specialized equipment and techniques during repeat procedures.

Why Pathway Location Matters

Not all accessory pathways are created equal when it comes to ablation difficulty. Pathways along the left side of the heart, which are among the most common, tend to be the most straightforward to eliminate. Pathways on the septum, the muscular wall dividing the two sides of the heart, are a different story. The septum is home to the heart’s normal electrical wiring, including the AV node and the His bundle, so ablating nearby tissue carries a risk of accidentally damaging those structures and causing permanent heart block, which would require a pacemaker.¹⁴

Data from the Pediatric Radiofrequency Ablation Registry put numbers on that risk. The rate of inadvertent heart block was about 10 percent for midseptal pathways and nearly 3 percent for anteroseptal pathways, compared with about 1 percent for right posteroseptal sites.¹⁵ The midseptal location is particularly unforgiving because the pathway sits almost on top of the normal conduction system. Operators tackling these pathways typically start at very low energy settings and ramp up cautiously, monitoring conduction through the AV node in real time.¹⁶

Cryoablation for High-Risk Locations

For septal pathways dangerously close to normal conduction tissue, many centers now use cryoablation instead of standard radiofrequency energy. Cryoablation works by freezing rather than burning the tissue, and it has a built-in safety feature: when the catheter tip is cooled to an intermediate temperature, it temporarily stuns the tissue. If that test freeze disrupts normal AV node conduction, the operator can stop and the effect reverses within seconds, avoiding permanent damage. A systematic review and meta-analysis comparing the two approaches found no cases of persistent heart block with cryoablation, compared with about 2.7 percent with radiofrequency ablation. However, cryoablation tends to be less effective overall, with lower acute success rates and higher recurrence rates than radiofrequency.¹⁷¹⁸

The trade-off is straightforward: cryoablation is safer for septal pathways but may need to be repeated. Three deaths have been reported in the radiofrequency cohort across the pooled studies, two in patients with underlying congenital heart disease, while no deaths have been reported with cryoablation.¹⁸ For pathways away from the septum, where the risk to normal conduction is minimal, standard radiofrequency remains the workhorse technique.

Pre-Excitation in Children

Pre-excitation discovered in a newborn or infant does not always stick around. A 30-year single-center study from South Wales found that spontaneous resolution of the delta wave occurred in about 43 percent of neonates and 35 percent of infants under one year, though across the entire pediatric cohort the overall resolution rate was 12 percent. The latest spontaneous disappearance in that study happened at age 17.¹⁹ Another study estimated that the probability of pre-excitation persisting dropped to about 53 percent by age one and roughly 34 percent by age 16.²⁰

Children whose pre-excitation comes and goes, so-called intermittent pre-excitation, are more likely to lose it altogether. Symptomatic children, particularly those reporting palpitations, are more likely to keep the pattern into adolescence and beyond.²⁰ These findings shape clinical decision-making: young infants with WPW are often managed conservatively with medication and monitoring, reserving ablation for children who remain symptomatic or show high-risk features as they grow. Ablation in very small children is technically harder, partly because of the smaller heart size and the close proximity of the normal conduction system to the coronary arteries.¹⁴

Athletes and Sports Clearance

Pre-excitation gets particular attention in athletes because intense exercise can trigger episodes and because sudden cardiac death during sport, while rare, is devastating. The American approach (based on Bethesda Conference guidelines) recommends invasive electrical testing for asymptomatic younger athletes competing in moderate- to high-intensity sports, plus catheter ablation for any athlete who has had symptoms. The European Society of Cardiology takes a more aggressive stance, recommending that all athletes with a WPW pattern on their ECG undergo a full electrophysiology study, regardless of symptom status or the intensity of their sport.²¹

In practice, many sports cardiologists push for ablation in competitive athletes even when the pathway appears low risk. The reasoning is partly medical and partly practical: an episode of tachycardia during competition could cause loss of consciousness in a dangerous setting, and the psychological burden of ongoing surveillance and activity restrictions is hard to sustain for years. Once a pathway has been successfully ablated and a brief recovery period has passed, most athletes return to full competition without restrictions.

Familial Patterns

WPW is not generally considered a genetic disease in the way that conditions like hypertrophic cardiomyopathy are, but family clustering does occur. A nationwide Swedish study looked at over 3,000 people diagnosed with WPW and found that having a sibling with the condition roughly quadrupled the risk, with an adjusted hazard ratio of about 3.8. Even so, familial cases were rare in absolute terms: only about 0.4 percent of all WPW cases in the study had an affected sibling.²² A small number of families carry mutations in specific genes that produce a combination of WPW and heart-muscle thickening, but for the vast majority of people the condition seems to arise sporadically during fetal heart development.

Living with a Pre-Excitation Diagnosis

For people who are told they have a WPW pattern after a routine ECG but have never felt anything wrong, the diagnosis itself can be a source of anxiety. A study comparing quality of life in asymptomatic children with WPW to healthy peers found no significant differences in physical or social well-being, but the WPW group reported lower general satisfaction with their health and were more likely to feel sad or nervous.²³ Children with pre-excitation also reported palpitations far more often than the control group, even in the absence of documented tachycardia episodes, suggesting heightened awareness of normal heartbeat sensations once a cardiac diagnosis is attached to them.

For adults in a similar position, the same dynamic plays out. The knowledge that you have an “extra wire” in your heart, combined with periodic medical visits and possible activity restrictions, can cast a shadow over daily life even when the pathway never causes a single arrhythmia. Shared decision-making between patient and cardiologist is the preferred framework for deciding whether to proceed with ablation in asymptomatic individuals.⁷ Factors that tip the balance toward ablation include high-risk pathway properties, an active lifestyle or occupation where a sudden arrhythmia would be particularly dangerous, and the patient’s own preference once the risks and benefits of the procedure versus ongoing monitoring have been clearly explained.